Literature DB >> 22356913

Direct evidence of generation and accumulation of β-sheet-rich prion protein in scrapie-infected neuroblastoma cells with human IgG1 antibody specific for β-form prion protein.

Toshiya Kubota1, Yuta Hamazoe, Shuhei Hashiguchi, Daisuke Ishibashi, Kazuyuki Akasaka, Noriyuki Nishida, Shigeru Katamine, Suehiro Sakaguchi, Ryota Kuroki, Toshihiro Nakashima, Kazuhisa Sugimura.   

Abstract

We prepared β-sheet-rich recombinant full-length prion protein (β-form PrP) (Jackson, G. S., Hosszu, L. L., Power, A., Hill, A. F., Kenney, J., Saibil, H., Craven, C. J., Waltho, J. P., Clarke, A. R., and Collinge, J. (1999) Science 283, 1935-1937). Using this β-form PrP and a human single chain Fv-displaying phage library, we have established a human IgG1 antibody specific to β-form but not α-form PrP, PRB7 IgG. When prion-infected ScN2a cells were cultured with PRB7 IgG, they generated and accumulated PRB7-binding granules in the cytoplasm with time, consequently becoming apoptotic cells bearing very large PRB7-bound aggregates. The SAF32 antibody recognizing the N-terminal octarepeat region of full-length PrP stained distinct granules in these cells as determined by confocal laser microscopy observation. When the accumulation of proteinase K-resistant PrP was examined in prion-infected ScN2a cells cultured in the presence of PRB7 IgG or SAF32, it was strongly inhibited by SAF32 but not at all by PRB7 IgG. Thus, we demonstrated direct evidence of the generation and accumulation of β-sheet-rich PrP in ScN2a cells de novo. These results suggest first that PRB7-bound PrP is not responsible for the accumulation of β-form PrP aggregates, which are rather an end product resulting in the triggering of apoptotic cell death, and second that SAF32-bound PrP lacking the PRB7-recognizing β-form may represent so-called PrP(Sc) with prion propagation activity. PRB7 is the first human antibody specific to β-form PrP and has become a powerful tool for the characterization of the biochemical nature of prion and its pathology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22356913      PMCID: PMC3340157          DOI: 10.1074/jbc.M111.318352

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding.

Authors:  G P Saborio; B Permanne; C Soto
Journal:  Nature       Date:  2001-06-14       Impact factor: 49.962

2.  PrPSc binding antibodies are potent inhibitors of prion replication in cell lines.

Authors:  Vincent Beringue; Didier Vilette; Gary Mallinson; Fabienne Archer; Maria Kaisar; Mourad Tayebi; Graham S Jackson; Anthony R Clarke; Hubert Laude; John Collinge; Simon Hawke
Journal:  J Biol Chem       Date:  2004-05-07       Impact factor: 5.157

3.  Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells.

Authors:  Cécile Féraudet; Nathalie Morel; Stéphanie Simon; Hervé Volland; Yveline Frobert; Christophe Créminon; Didier Vilette; Sylvain Lehmann; Jacques Grassi
Journal:  J Biol Chem       Date:  2004-12-23       Impact factor: 5.157

4.  NMR solution structure of the human prion protein.

Authors:  R Zahn; A Liu; T Lührs; R Riek; C von Schroetter; F López García; M Billeter; L Calzolai; G Wider; K Wüthrich
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

5.  Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay.

Authors:  J D Wadsworth; S Joiner; A F Hill; T A Campbell; M Desbruslais; P J Luthert; J Collinge
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

6.  Human anti-human IL-18 antibody recognizing the IL-18-binding site 3 with IL-18 signaling blocking activity.

Authors:  Takayuki Hamasaki; Shuhei Hashiguchi; Yuji Ito; Zenichiro Kato; Kenji Nakanishi; Toshihiro Nakashima; Kazuhisa Sugimura
Journal:  J Biochem       Date:  2005-10       Impact factor: 3.387

7.  Purification and structural studies of a major scrapie prion protein.

Authors:  S B Prusiner; D F Groth; D C Bolton; S B Kent; L E Hood
Journal:  Cell       Date:  1984-08       Impact factor: 41.582

8.  Scrapie prions aggregate to form amyloid-like birefringent rods.

Authors:  S B Prusiner; M P McKinley; K A Bowman; D C Bolton; P E Bendheim; D F Groth; G G Glenner
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

9.  Human Fc epsilon RIalpha-specific human single-chain Fv (scFv) antibody with antagonistic activity toward IgE/Fc epsilon RIalpha-binding.

Authors:  Shuhei Hashiguchi; Toshihiro Nakashima; Aya Nitani; Tomoki Yoshihara; Keisuke Yoshinaga; Yuji Ito; Yoshio Maeda; Kazuhisa Sugimura
Journal:  J Biochem       Date:  2003-01       Impact factor: 3.387

10.  Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies.

Authors:  Kensuke Ishikawa; Katsumi Doh-Ura; Yukitsuka Kudo; Noriyuki Nishida; Ikuko Murakami-Kubo; Yukio Ando; Tohru Sawada; Toru Iwaki
Journal:  J Gen Virol       Date:  2004-06       Impact factor: 3.891

View more
  4 in total

1.  Role of lipid rafts and GM1 in the segregation and processing of prion protein.

Authors:  Laura Botto; Diana Cunati; Silvia Coco; Silvia Sesana; Alessandra Bulbarelli; Emiliano Biasini; Laura Colombo; Alessandro Negro; Roberto Chiesa; Massimo Masserini; Paola Palestini
Journal:  PLoS One       Date:  2014-05-23       Impact factor: 3.240

Review 2.  Prion protein-specific antibodies-development, modes of action and therapeutics application.

Authors:  Tihana Lenac Rovis; Giuseppe Legname
Journal:  Viruses       Date:  2014-10-01       Impact factor: 5.048

3.  Exposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril.

Authors:  Changyoun Kim; Guohua Lv; Jun Sung Lee; Byung Chul Jung; Masami Masuda-Suzukake; Chul-Suk Hong; Elvira Valera; He-Jin Lee; Seung R Paik; Masato Hasegawa; Eliezer Masliah; David Eliezer; Seung-Jae Lee
Journal:  Sci Rep       Date:  2016-08-04       Impact factor: 4.379

Review 4.  Single-chain fragment variable passive immunotherapies for neurodegenerative diseases.

Authors:  Liang Huang; Xiaomin Su; Howard J Federoff
Journal:  Int J Mol Sci       Date:  2013-09-17       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.